Which 36 drugs are included in the medical insurance?
4hw.org: after three months of negotiation, 36 drugs have been included in the national gross package, which means that these drugs can be reimbursed with medical insurance to benefit patients. What are the 36 drugs included in the medical insurance? Let's take a look at them!
On July 19, the official website of the Ministry of human resources and social security released the negotiation results on the access of medical insurance drug catalog, 36 drugs were included in the category B scope of the national basic medical insurance, industrial injury insurance and maternity insurance drug catalog (2017 version) (hereinafter referred to as "drug catalog"). The Ministry of human resources and Social Security announced the medical insurance payment standards for these drugs at the same time. The reporter combed and found that among these 36 varieties, 8 A-share listed companies' heavyweight new drug varieties were shortlisted. A person in charge of a listed company told reporters that the inclusion of the product in the medical insurance catalog will benefit more patients, and the company's sales volume is expected to further expand, which will be conducive to improving the company's business performance in the future.
It is understood that 44 drugs participated in the negotiation, 36 of which were successfully negotiated, and were included in the category B scope of the drug catalog, with a success rate of 81.8%. Compared with the average retail price in 2016, the payment standard determined through negotiation has an average decrease of 44%, with the highest decrease of 70%, which has obviously reduced the burden of medical expenses of the insured, and effectively controlled the expenditure of medical insurance fund. This article is compiled by sihai.com.cn and reprinted with the source. The original link: http://www.4hw.com.cn/life/
The 36 drugs successfully negotiated include 31 Western medicines and 5 Chinese patent medicines. Of the 31 Western medicines, 15 are tumor drugs, involving lung cancer, gastric cancer, breast cancer, myeloma and other common cancer types, including trastuzumab, rituximab, bortezomib, lenalidomide, etc., which were more frequently reported by the insured before; 5 are cardiovascular drugs; other drugs are kidney disease, ophthalmology, psychiatry, anti infection, diabetes and rare diseases. Of the 5 traditional Chinese medicines, 3 are tumor drugs, and 2 are cardio cerebrovascular drugs.
It is worth noting that this negotiation attaches great importance to innovative drugs and rare disease drugs. Since the 12th Five Year Plan, all the negotiations on sidabamide, conbercept and apatinib, which are listed as the national major new drug development projects, have been successful. Recombinant human coagulation factor ⅶ a for hemophilia and recombinant human interferon beta for multiple sclerosis have also been successfully included in the drug catalog.
Yesterday, Xu Yanjun, deputy director of the social security center of the Ministry of human resources and social security, said in an interview that through negotiations, drugs for treatment of major diseases such as tumor targeted drugs, which are strongly reflected by the society, have been included in the drug catalog, greatly improving the level of basic medical insurance, taking into account the fund burden capacity, and helping to guide rational medical behavior, promote the development and innovation of the pharmaceutical industry, and basically achieve The goal of "three wins" for medical insurance, enterprises and insured is achieved. "Next, we will guide the local government to earnestly implement the negotiation results and ensure that this important policy of benefiting the people can be implemented as soon as possible so that the masses of the people can truly benefit. This article is compiled by sihai.com.cn and reprinted with reference to the source. The original link: http://www.4hw.com.cn/life/
The reporter noted that among the 36 successfully negotiated varieties, 8 listed companies including Tianshi (60053.5), Yifan medicine and xinlitai (002294) were shortlisted, which is expected to bring good news to the common people (603883) in the treatment of major diseases, such as apatinib mesylate (gastric cancer medicine), the heavyweight NEW drug of Hengrui medicine (600276), compound Huangdai tablet (white blood medicine), the exclusive variety of Yifan medicine Disease medication), conbercept ophthalmic injection (macular degeneration medication) of Kanghong Pharmaceutical (002773), alisartan ester tablet (antihypertensive medication) of xinlitai, and Shenyi capsule, a new anti-cancer drug of Yatai group (600881).
It is reported that the recombinant human urokinase for injection, which was selected by Tianshili this time, was a class of new drugs listed by the company in 2011 and a major national science and technology project for new drug creation. The drug is mainly used in the treatment of acute myocardial infarction caused by thrombus. Compared with the same foreign varieties, it has advantages in efficacy and price, and is expected to become more than 10 billion varieties in the future. This article is compiled by sihai.com.cn and reprinted with the source. The original link: http://www.4hw.com.cn/life/
Similarly, Yifan pharmaceutical's compound Huangdai tablet is the exclusive product of the company, which is mainly used for the treatment of leukemia. The head of the company said in an interview: 'the product has been listed in the local medical insurance catalogue before, and it is expected to further expand the sales volume of the product after entering the national negotiation catalogue this time. However, the growth of sales volume still needs a time process and will not be effective in the short term. It is worth mentioning that in this year's new version of the medical insurance catalog, Yifan medicine has 11 major varieties, which is a great harvest. The company said that the inclusion of the product in the medical insurance catalogue will benefit more patients and improve the company's business performance.
In addition, Professor Shen Shuguang, vice president of the Chinese Social Security Society and vice president of the National Institute of governance of Sun Yat sen University, said in an interview that on the one hand, the negotiated drugs for medical insurance reflect the recognition and support of the state for the innovative drug industry, and further encourage the innovation and research and development of domestic pharmaceutical enterprises; on the other hand, they also guarantee the use of drugs for patients with major and major diseases from the perspective of medical insurance fund, which is helpful to reduce the number of patients People's economic burden is of great significance（